Suscripción a Biblioteca: Guest
International Journal of Medicinal Mushrooms

Publicado 12 números por año

ISSN Imprimir: 1521-9437

ISSN En Línea: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

Pharmacological Investigation of Ceraceomyces tessulatus (Agaricomycetes) in Mice with Nonalcoholic Steatohepatitis

Volumen 22, Edición 7, 2020, pp. 683-692
DOI: 10.1615/IntJMedMushrooms.2020035048
Get accessGet access

SINOPSIS

Nonalcoholic steatohepatitis (NASH) is becoming the most common cause of hepatocellular carcinoma (HCC). Natural products including edible mushrooms are gaining attention for the prevention and treatment of lifestyle related disorders. Ceraceomyces tessulatus (strain BDM-X) possesses potent antioxidative stress activity. In this study, we hypothesize that BDM-X treatment protects the liver of mouse with NASH by reducing inflammation in a novel NASH-HCC mouse model. C57BL/6J female pups were exposed to low-dose streptozotocin (STZ) and fed a high-fat diet (HFD) 32 from the age of 4 weeks to 16 weeks. Water extract of BDM-X was given at 500 mg/kg dose daily by oral gavage started at the age of 12 weeks and continued until 16 weeks of age along with HFD feeding. We found that BDM-X improved the histopathological changes, serum aminotransferases, and blood glucose levels in NASH mice. The hepatic protein expressions of SIRT1 and IL-10 were significantly repressed in NASH mice. BDM-X treatment restored these expressions. BDM-X treatment effectively reduced the progression of NASH by suppressing the protein expression of SREBPlc, p-NF-κB, Ep-CAM, and prothrombin in the NASH liver. In conclusion, our data suggest that BDM-X can protect the liver against inflammation and lipogenesis in NASH-HCC mice.

REFERENCIAS
  1. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-38.

  2. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. J Hepatol. 2013;58(6):1218-29.

  3. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H, Yoneyama H. A murine model for nonalcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46(3):141-52.

  4. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. Gut Liver. 2012;6(2):149-71.

  5. Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203-12.

  6. Wasser SP. Medicinal mushroom science: History, current status, future trends, and unsolved problems. Int J Med Mushooms. 2010,12(1):1-16.

  7. Wasser SP. Medicinal mushrooms in human clinical studies. Part 1. Anticancer, oncoimmunological, and immunomodulatory activities: A review. Int J Med Mushrooms. 2017;19(4):279-317.

  8. Hida TH, Kawaminami H, Ishibashi K, Miura NN, Adachi Y, Ohno N. Oral administration of soluble beta-glucan preparation from the cauliflower mushroom, Sparassis crispa (higher Basidiomycetes) modulated cytokine production in mice. Int J Med Mushrooms. 2013;15(6):525-38.

  9. Tada R, Adachi Y, Ohno N. A concise method using nuclear magnetic resonance spectroscopy to determine the source of the beta-glucan extracted from various mushrooms. Int J Med Mushrooms. 2012;14(4):339-45.

  10. Watanabe T, Nakajima Y, Konishi T. In vitro and in vivo anti-oxidant activity of hot water extract of Basidiomycetes-X, newly identified edible fungus. Biol Pharm Bull. 2008;31(1):111-7.

  11. Mizuno T. Development of an antitumor biological response modifier from Phellinus linteus (Berk. et Curt.) Teng (Aphyllo-phoromycetidae) (review). Int J Med Mushrooms. 2000;2(1):13-24.

  12. Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, Shrode GE, Belury M, Adams LS, Williams D. Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res. 2006;66(24):12026-34.

  13. Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, Ma S, Ng IO, Wong YC, Chan FL, Ling MT. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One. 2011;6(5):e19804.

  14. Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, Nagamori N, Yanagita T. Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice. J Nutr Biochem. 2010;21(5):418-23.

  15. Hagiwara SY, Takahashi M, Shen Y, Kaihou S, Tomiyama T, Yazawa M, Tamai Y, Sin Y, Kazusaka A, Terazawa M. A phy- tochemical in the edible tamogi-take mushroom (Pleurotus cornucopiae), d-mannitol, inhibits ACE activity and lowers the blood pressure of spontaneously hypertensive rats. Biosci Biotechnol Biochem. 2005;69(8):1603-5.

  16. Wang JCY, Hu SH, Wang JT, Chen KS, Chia YC. Hypoglycemic effect of extract of Hericium erinaceus. J Sci Food Agr. 2005;85(4):641-46.

  17. Ikekawa T. Beneficial effects of edible and medicinal mushrooms on health care. Int J Med Mushrooms. 2001;3(4):1-8.

  18. Matsuzawa T. Studies on antioxidant effects of culinary-medicinal bunashimeji mushroom Hypsizygus marmoreus (Peck) Begel. (Agaricomycetidae). Int J Med Mushrooms. 2006;8(3):245-50.

  19. Minami K, Watanabe T, Yukami S, Nomoto K. Clinical trials of Basidiomycetes-X on the patients with atopic dermatitis. Med Biol. 2007;151(9):306-11.

  20. Fujikawa T, Shiraha H, Yamamoto K. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med Okayama. 2009;63(6):299-304.

  21. Afrin R, Arumugam S, Rahman A, Wahed MI, Karuppagounder V, Harima M, Suzuki H, Miyashita S, Suzuki K, Yoneyama H, Ueno K, Watanabe K. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-kappaB translocation. Int Immunopharmacol. 2017;44:174-82.

  22. Afrin R, Arumugam S, Soetikno V, Thandavarayan RA, Pitchaimani V, Karuppagounder V, Sreedhar R, Harima M, Suzuki H, Miyashita S, Nomoto M, Suzuki K, Watanabe K. Curcumin ameliorates streptozotocin-induced liver damage through modulation of endoplasmic reticulum stress-mediated apoptosis in diabetic rats. Free Radic Res. 2015;49(3):279-89.

  23. Li X. SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai). 2013;45(1):51-60.

  24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

  25. Hefaiedh R, Ennaifer R, Romdhane H, Ben Nejma H, Arfa N, Belhadj N, Gharbi L, Khalfallah T. Gender difference in patients with hepatocellular carcinoma. Tunis Med. 2013;91(8-9):505-8.

  26. Pasumarthy L, Srour J. Nonalcoholic steatohepatitis: A review of the literature and updates in management. South Med J. 2010;103(6):547-50.

  27. Watanabe T, inventor; Mycology Techno Corp, assignee. Basidiomycetes, basidiomycetes extract composition, health foods, and immunopotentiators. USA patent CA2523895. 2004 Nov 11.

  28. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression. Hepatology. 2006;43(3):506-14.

  29. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-31.

  30. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434(7029):113-8.

  31. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirtl protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793-8.

  32. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327-38.

  33. Tak PP, Firestein GS. NF-kappaB: A key role in inflammatory diseases. J Clin Invest. 2001;107(1):7-11.

  34. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369-80.

  35. Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: Study on C57BL/6J mice. BMC Cancer. 2016;16(1):3-17.

  36. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280-1.

CITADO POR
  1. Sakamoto Toshio, Nishida Ayaka, Wada Naoki, Nakamura Yutaka, Sato Shinji, Konishi Tetsuya, Matsugo Seiichi, Identification of a Novel Pyrrole Alkaloid from the Edible Mushroom Basidiomycetes-X (Echigoshirayukidake), Molecules, 25, 21, 2020. Crossref

  2. Matsugo Seiichi, Sakamoto Toshio, Wakame Koji, Nakamura Yutaka, Watanabe Kenichi, Konishi Tetsuya, Mushrooms as a Resource for Mibyou-Care Functional Food; The Role of Basidiomycetes-X (Shirayukidake) and Its Major Components, Nutraceuticals, 2, 3, 2022. Crossref

1597 Vistas de artículos 36 Descargas de artículos Métrica
1597 PUNTOS DE VISTA 36 DESCARGAS 2 Crossref CITAS Google
Scholar
CITAS

Artículos con contenido similar:

Meal Ingestion of Ceraceomyces tessulatus Strain BDM-X (Agaricomycetes) Protects against Nonalcoholic Steatohepatitis in Mice International Journal of Medicinal Mushrooms, Vol.24, 2022, issue 1
Manoj Limbraj Yellurkar, Remya Sreedhar, Hiroshi Suzuki, Somasundaram Arumugam, Kenichi Watanabe, Rejina Afrin, Hirohito Sone
Chemopreventive Action of Diclofenac in Dimethybenzanthracene Induced Lung Cancer in Female Wistar Rat Journal of Environmental Pathology, Toxicology and Oncology, Vol.29, 2010, issue 3
Sankar Nath Sanyal, Poonam Thakur
Extract of Caterpillar Medicinal Mushroom, Cordyceps milifaris (Ascomycetes), Mycelia Attenuates Doxorubicin-Induced Cardiotoxicity and Upregulates Mitochondrial Electron Transport Chain Activity in Rats International Journal of Medicinal Mushrooms, Vol.23, 2021, issue 1
Thekkuttuparambil Ananthanarayanan Ajith, Kainoor Krishnankutty Janardhanan, Solomon P. Wasser, Ravindran Kalathil Veena, Haridas Ramya
Lead Acetate-Induced Hepatoxicity in Wistar Rats: Possible Protective Role of Combination Therapy Journal of Environmental Pathology, Toxicology and Oncology, Vol.34, 2015, issue 1
Amita Jaswal, Sadhana Shrivastava, Samta Sharma, Suchita Raghuvanshi, Sangeeta Shukla
Protective Effect of Acacia ferruginea against Ulcerative Colitis via Modulating Inflammatory Mediators, Cytokine Profile and NF-κB Signal Transduction Pathways Journal of Environmental Pathology, Toxicology and Oncology, Vol.33, 2014, issue 2
Chandrasekaran Guruvayoorappan, Kunnathur Murugesan Sakthivel
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain